维奈克拉联合氟达拉滨/白消安RIC移植治疗高危MDS和AML可行安全且有效
这项1期研究在22例接受移植的高危AML、MDS及MDS/MPN成人患者中,将BCL-2抑制剂维奈克拉加入氟达拉滨/白消安(FluBu2)减低强度预处理方案。未观察到剂量限制性毒性,推荐2期剂量为维奈克拉每日400 mg共7剂;中位随访14.7个月,中位总生存未达到,无进展生存12.2个月。
要点
- 维奈克拉联合FluBu2方案未观察到剂量限制性毒性。
- 推荐2期剂量为维奈克拉每日400 mg共7剂。
- 中位无进展生存12.2个月,中位总生存未达到。
核心结论
- 在高危AML、MDS和MDS/MPN患者中,维奈克拉加入FluBu2预处理可行且安全。
研究设计与样本
- 1期剂量递增研究,共治疗22例接受移植的成人高危AML、MDS及MDS/MPN患者。
主要发现
- 22例中18例(82%)在入组时可检测到持续突变。
- 3级不良事件包括黏膜炎、腹泻和肝转氨酶升高,各3例。
- 中性粒细胞/血小板恢复及急慢性GVHD发生率与标准FluBu2相似。
- 未观察到剂量限制性毒性,推荐2期剂量为维奈克拉每日400 mg共7剂。
- 中位随访14.7个月(范围8.6-24.8个月),中位总生存未达到,无进展生存12.2个月(95%CI 6.0-不可估计)。
关键数值与推荐
- 维奈克拉剂量递增范围为每日200-400 mg,自第-8天开始共6-7剂。
- 氟达拉滨30 mg/m2每日共4剂,白消安0.8 mg/kg每日两次共8剂(第-5天至第-2天)。
- 移植相关毒性评估从第-8天首剂维奈克拉至第28天。
临床怎么用
- 维奈克拉联合FluBu2可作为高危AML、MDS和MDS/MPN患者移植前预处理的可行选择。
- 推荐2期剂量为维奈克拉每日400 mg共7剂联合FluBu2。
- 为降低移植后复发风险,维奈克拉联合FluBu2移植后维持治疗的评估正在进行。
局限性
- 研究为1期剂量递增研究,样本量22例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adding the selective BCL-2 inhibitor venetoclax to reduced-intensity conditioning chemotherapy (fludarabine and busulfan [FluBu2]) may enhance antileukemic cytotoxicity and thereby reduce the risk of posttransplant relapse. This phase 1 study investigated the recommended phase 2 dose (RP2D) of venetoclax, a BCL-2 selective inhibitor, when added to FluBu2 in adult patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and MDS/myeloproliferative neoplasms (MPN) undergoing transplant. Patients received dose-escalated venetoclax (200-400 mg daily starting day -8 for 6-7 doses) in combination with fludarabine 30 mg/m2 per day for 4 doses and busulfan 0.8 mg/kg twice daily for 8 doses on day -5 to day -2 (FluBu2). Transplant related-toxicity was evaluated from the first venetoclax dose on day -8 to day 28. Twenty-two patients were treated. At study entry, 5 patients with MDS and MDS/MPN had 5% to 10% marrow blasts, and 18 (82%) of 22 had a persistent detectable mutation. Grade 3 adverse events included mucositis, diarrhea, and liver transaminitis (n = 3 each). Neutrophil/platelet recovery and acute/chronic graft-versus-host-disease rates were similar to those of standard FluBu2. No dose-limiting toxicities were observed. The RP2D of venetoclax was 400 mg daily for 7 doses. With a median follow-up of 14.7 months (range, 8.6-24.8 months), median overall survival was not reached, and progression-free survival was 12.2 months (95% confidence interval, 6.0-not estimable). In patients with high-risk AML, MDS, and MDS/MPN, adding venetoclax to FluBu2 was feasible and safe. To further address relapse risk, assessment of maintenance therapy after venetoclax plus FluBu2 transplant is ongoing. This study was registered at clinicaltrials.gov as #NCT03613532.
引用
- Garcia JS, Kim HT, Murdock HM, et al. Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021. PMID: 34614506. doi:10.1182/bloodadvances.2021005566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。